PPAR-γ (peroxisome proliferator-activated receptor gamma) agonists, such as pioglitazone, were initially introduced to treat insulin resistance in type II diabetes mellitus, showing the ability to reduce albuminuria. This evidence concerns the gene PPARG and Insulin resistance.